Mesoblast targets AMD and retinopathy
Thursday, 10 July, 2008
Mesoblast [ASX: MSB] today released results from its sister company Angioblast's pre-clinical trials into using adult stem cells to treat ocular diseases association with abnormal blood vessels.
Trials involving 42 non-human primates indicates that an injection of Mesoblast's proprietary adult stem cells combined with an anti-VEGF agent were able to reduce the number of leaking blood vessels - a major cause of ocular disease - more effectively than using an anti-VEGF agent alone.
The combination also reduced the number of subsequent anti-VEGF injections required in the primates.
The results of this trial will comprise part of the company's IND application to the US FDA.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
